NZNZ.1023 - Grafton - Starship Children's Hospital (SUSPENDED)NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (SUSPENDED)

NCT04870944

A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma (PEPN2111)

NSW2031 - Randwick - Sydney Children's Hospital (SUSPENDED)

NCT04775485

FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors

NCT04774718

A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available (GO42286)

NCT04655404

A Pilot and Surgical Study of Larotrectinib for Treatment of Children With Newly-Diagnosed High-Grade Glioma With NTRK Fusion (CONNECT1903)

NCT04625907

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

NCT04323046

A Single Arm, Pilot of Neoadjuvant Checkpoint Inhibition Followed by Adjuvant Checkpoint Inhibition in Children and Young Adults With Recurrent or Progressive High Grade Glioma (HGG)

NCT04293562

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations (AAML1831)

NCT04221035

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (HR-NBL2)

2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)

WA6009 - Perth - Perth Children's Hospital (SUSPENDED)

NCT04094610

A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations (CA127-1029)

NCT03838042

INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies (INFORM2-NivEnt) (Final4,-18-10-2023)

NCT02724163

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy (Myechild01)

NCT06838676

A Phase II Trial of ACT001 in Children and Adolescents With Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas (CONNECT2110)

Filters

Recruitment Status

Recruitment Country and State

Phase

Trial Type

Cancer Therapy Class

BRAF	17%
RAF	17%
ALK	13%
CRAF	13%
pan-RAF	13%
ROS1	8%
mTOR	8%
mTORC1	8%
RET	8%
TRK	8%
PD-1	8%
PD-1/PD-L1	8%
CD33	8%
ROR1	4%
DPD	4%
orotate phosphoribosyltransferase	4%
PI3K	4%
PI3K alpha	4%
PI3K delta	4%
mTORC2	4%
IDH1	4%
IDH1 R132	4%
CDK4	4%
CDK6	4%
CD19	4%
XPO1	4%
FACT complex	4%
FGFR	4%
FGFR1	4%
FGFR1/2/3	4%
FGFR2	4%
FGFR3	4%
FGFR4	4%
KIT	4%
PDGFR	4%
VEGFR	4%
AXL	4%
FLT3	4%
GD2	4%
HDAC	4%
NFKB	4%

Facility

Cancer Type

ARTICANZ - Beta (ver 0.91)

Search results

Filters